Compare
Kalaris Therapeutics, Inc. vs Acumen Pharmaceuticals, Inc. vs Candel Therapeutics, Inc. vs Humacyte, Inc.
| Latest fiscal year | Kalaris Therapeutics, Inc. KLRS | Acumen Pharmaceuticals, Inc. ABOS | Candel Therapeutics, Inc. CADL | Humacyte, Inc. HUMA |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | n/a | n/a | $2.04M |
| Revenue growth (YoY) | n/a | n/a | n/a | n/a |
| Gross margin | n/a | n/a | n/a | -376.1% (computed) |
| Operating margin | n/a | n/a | n/a | n/m |
| Net margin | n/a | n/a | n/a | n/m |
| Net income | -$43.44M | -$121.33M | -$38.18M | -$40.83M |
| EPS (Diluted) | -$2.85 | -$2.00 | -$0.72 | -$0.26 |
| Operating cash flow | -$38.37M | -$115.54M | -$38.31M | -$105.04M |
| Free cash flow | -$38.57M | -$115.63M | -$38.90M | -$105.93M |
| Cash & equivalents | $98.05M | $53.99M | $119.73M | $50.50M |
| Total assets | $121.74M | $122.83M | $125.19M | $116.37M |
| Total liabilities | $42.92M | $52.40M | $73.27M | $113.26M |
| Shareholders' equity | $78.81M | $70.43M | $51.92M | $3.11M |
| Return on year-end equity | -55.1% | -172.3% | -73.5% | n/m |
| Shares outstanding | 22.90M | 60.58M | 54.90M | 193.00M |
Revenue, most recent five fiscal years
| Fiscal year | Kalaris Therapeutics, Inc. | Acumen Pharmaceuticals, Inc. | Candel Therapeutics, Inc. | Humacyte, Inc. |
|---|---|---|---|---|
| Latest | $165.0K Ended 2019-12-31 | n/a | $125.0K Ended 2022-12-31 | $2.04M Ended 2025-12-31 |
| 1 year earlier | n/a | n/a | $125.0K Ended 2021-12-31 | $0 Ended 2024-12-31 |
| 2 years earlier | n/a | n/a | $125.0K Ended 2020-12-31 | n/a |
| 3 years earlier | n/a | n/a | n/a | n/a |
| 4 years earlier | n/a | n/a | n/a | n/a |